A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

[1]  A. Morris,et al.  A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children. , 2009, The Journal of clinical endocrinology and metabolism.

[2]  A. Morris,et al.  A Single Nucleotide Polymorphism on Exon-4 of the Gene Encoding PPAR (cid:1) Is Associated with Reduced Height in Adults and Children , 2009 .

[3]  Elmar Bucher,et al.  Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients , 2008, Genes, chromosomes & cancer.

[4]  S. Steinberg,et al.  ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel , 2008, Clinical Cancer Research.

[5]  Francis J McMahon,et al.  Association study of Wnt signaling pathway genes in bipolar disorder. , 2008, Archives of general psychiatry.

[6]  S. Steinberg,et al.  Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel , 2008, Molecular Cancer Therapeutics.

[7]  M. Maitland,et al.  Interpreting P values in pharmacogenetic studies: a call for process and perspective. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Venzon,et al.  Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. , 2007, Urology.

[9]  Philip Hahnfeldt,et al.  Transcriptional network governing the angiogenic switch in human pancreatic cancer , 2007, Proceedings of the National Academy of Sciences.

[10]  A. Krook,et al.  Role of AMP Kinase and PPARδ in the Regulation of Lipid and Glucose Metabolism in Human Skeletal Muscle* , 2007, Journal of Biological Chemistry.

[11]  D. Schaid,et al.  Genetic diversity and function in the human cytosolic sulfotransferases , 2007, The Pharmacogenomics Journal.

[12]  A. El-Husseini,et al.  NIPA1(SPG6), the Basis for Autosomal Dominant Form of Hereditary Spastic Paraplegia, Encodes a Functional Mg2+ Transporter* , 2007, Journal of Biological Chemistry.

[13]  P. Hardenbol,et al.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.

[14]  S. Bates,et al.  Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics , 2007, Anti-cancer drugs.

[15]  W. M. Smit,et al.  Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel , 2006, Clinical Cancer Research.

[16]  S. Bates,et al.  Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib , 2006, Clinical pharmacology and therapeutics.

[17]  W. Figg,et al.  Thalidomide metabolism and hydrolysis: mechanisms and implications. , 2006, Current drug metabolism.

[18]  C. Chau,et al.  Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics , 2006, Cancer biology & therapy.

[19]  J. Verweij,et al.  Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel , 2006, Cancer biology & therapy.

[20]  F. Goldwasser,et al.  Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms , 2006, Clinical pharmacology and therapeutics.

[21]  M. Laakso,et al.  Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. , 2005, Diabetes.

[22]  S. Bates,et al.  Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients , 2005, Clinical Cancer Research.

[23]  J. Chang,et al.  Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling , 2005 .

[24]  R. Hume,et al.  Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification , 2005, Molecular and Cellular Endocrinology.

[25]  T. Thalhammer,et al.  Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. , 2005, International journal of oncology.

[26]  S. Howell,et al.  Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.

[27]  C. Baines,et al.  Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. , 2004, International journal of epidemiology.

[28]  B. Palmer,et al.  Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[29]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Dalenc,et al.  Dexamethasone as a probe for docetaxel clearance , 2004, Cancer Chemotherapy and Pharmacology.

[31]  J. Verweij,et al.  Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel , 2004, Clinical pharmacology and therapeutics.

[32]  René Bruno,et al.  Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel , 2001, Investigational New Drugs.

[33]  T. Imai,et al.  Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. , 2004, Drug metabolism and pharmacokinetics.

[34]  A. Hamsten,et al.  Evidence That Peroxisome Proliferator–Activated Receptor Delta Influences Cholesterol Metabolism in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[35]  J. Boyer,et al.  Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.

[36]  M. Miyata,et al.  Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[37]  J. Rigas,et al.  Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Y. Ando,et al.  Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide , 2002, Cancer biology & therapy.

[39]  S. Bates,et al.  Single-Nucleotide Polymorphism (SNP) Analysis in the ABC Half-Transporter ABCG2 (MXR/BCRP/ABCP1) , 2002, Cancer biology & therapy.

[40]  Zhe-Sheng Chen,et al.  Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). , 2002, Cancer research.

[41]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  W. Figg,et al.  Thalidomide metabolism by the CYP2C subfamily. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  K. Tanimoto,et al.  Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. , 2002, International Journal of Oncology.

[44]  W. Figg,et al.  5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis , 2002, Therapeutic drug monitoring.

[45]  A. Sekine,et al.  Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes , 2002, Journal of Human Genetics.

[46]  H. Tamura,et al.  Expression profiling of sulfotransferases in human cell lines derived from extra-hepatic tissues. , 2001, Biological & pharmaceutical bulletin.

[47]  T. Tedder,et al.  CHST1 and CHST2 sulfotransferase expression by vascular endothelial cells regulates shear‐resistant leukocyte rolling via l‐selectin , 2001, Journal of leukocyte biology.

[48]  D. Hartmann,et al.  Enzymatic properties, tissue-specific expression, and lysosomal location of two highly homologous rat SULT1C2 sulfotransferases. , 2000, Biochemical and biophysical research communications.

[49]  P. Watkins,et al.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  P. Sabourin,et al.  Metabolism of thalidomide in human microsomes, cloned human cytochrome P‐450 isozymes, and Hansen’s disease patients , 2000, Journal of biochemical and molecular toxicology.

[51]  L. Rivory,et al.  Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.

[52]  K. Korzekwa,et al.  Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.

[53]  Sergio Cocozza,et al.  Spastic Paraplegia and OXPHOS Impairment Caused by Mutations in Paraplegin, a Nuclear-Encoded Mitochondrial Metalloprotease , 1998, Cell.

[54]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  P. V. van Helden,et al.  Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. , 1997, American journal of respiratory and critical care medicine.

[56]  J. Lo-Guidice,et al.  NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. , 1997, Pharmacogenetics.

[57]  J. Beijnen,et al.  Isolation, purification and biological activity of major docetaxel metabolites from human feces. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[58]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[59]  B. Monsarrat,et al.  Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. , 1996, Cancer research.

[60]  S. Weinreb,et al.  Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. , 1985, Teratogenesis, carcinogenesis, and mutagenesis.

[61]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[62]  R. T. Williams,et al.  The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. , 1965, British journal of pharmacology and chemotherapy.